Drug Profile
Certolizumab pegol biosimilar - PanPharmaceuticals USA
Latest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator PanPharmaceuticals USA
- Class Anti-inflammatories; Antirheumatics; Fab fragments; Monoclonal antibodies; Polyethylene glycols
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 17 Jun 2015 PanPharmaceuticals USA has ceased its operations
- 16 Jun 2015 Discontinued for Autoimmune disorders in USA (unspecified route)